Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders

RTTNews | il y a 1036
Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders

(RTTNews) - Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.

EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

The company said this trial brings us one step closer to a new treatment option for underserved cancer patients as there is no specific treatment currently approved for the treatment of skin toxicities associated with EGFRi therapies.

The company added it will advance HT-001 into the clinical phase as it is a key treatment in the onco-dermatology space and anticipates beginning the Phase 2a trial in the first quarter of 2023.

read more
Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA

Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA

Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM), a rare aggressive form of cancer.
RTTNews | il y a 780
ECB Holds Interest Rates Steady Amid Uncertain Outlook

ECB Holds Interest Rates Steady Amid Uncertain Outlook

The European Central Bank maintained its key interest rates unchanged for a third policy session in a row on Thursday, as expected, as policymakers assessed that the outlook was broadly unchanged, but still uncertain due to global trade conflicts and geopolitical tensions.
RTTNews | il y a 3h 54min
Eurozone GDP Growth Beats Expectations

Eurozone GDP Growth Beats Expectations

The euro area economy expanded at a faster pace in the third quarter as France and Spain reported strong growth, while Germany and Italy experienced stagnation, amid a highly uncertain outlook due to the ongoing trade policies and political instability. Gross domestic product climbed 0.2 percent sequentially in the September quarter, preliminary flash estimate from Eurostat showed on Thursday.
RTTNews | il y a 4h 39min
Bay Street Likely To Open Weak

Bay Street Likely To Open Weak

Weak commodity prices, lower European stocks and U.S. and Canadian futures point to a negative start for the Canadian market on Thursday. The Federal Reserve and Bank of Canada lowered interest rates on Wednesday but have ruled out the possibility of another cut this year.
RTTNews | il y a 5h 32min
German Economy Stagnates On Weaker Exports; Unemployment Falls

German Economy Stagnates On Weaker Exports; Unemployment Falls

The German economy stagnated in the third quarter, narrowly dodging a recession as higher U.S. tariffs damped exports and the optimism about the fiscal stimulus faded, while unemployment logged an unexpected moderate fall. Gross domestic product remained unchanged, as expected, following a revised decline of 0.2 percent in the second quarter, the preliminary estimate from Destatis revealed on T
RTTNews | il y a 5h 35min